1
|
Zhang XY, Wang L, Jiang Y, Huang SM, Zhu HR, Liu W, Wang JY, Wei XH, Zhao YL, Wei WJ, Fei T, Chen XH, Wang D, Li JL, Ling H, Zhuang M. Low CD4 count was characterized in recent HIV CRF01_AE infection and it rapidly increased to reach a peak in the first year since ART initiation. BMC Infect Dis 2025; 25:443. [PMID: 40165131 PMCID: PMC11956320 DOI: 10.1186/s12879-025-10799-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2024] [Accepted: 03/13/2025] [Indexed: 04/02/2025] Open
Abstract
BACKGROUND Currently, most people living with HIV (PLWH) in China have a strong awareness of diagnosis and treatment in the early stage of HIV infection. Subtype-specific virological and immunological features of recently infected PLWH have not yet been elucidated. METHODS Data including CD4 count and viral load (VL) of 1508 anti-retroviral therapy (ART) -naïve PLWH were obtained from the HIV Database and comparatively analyzed among PLWH with different HIV subtypes. The infection status of 402 newly diagnosed and ART-naïve PLWH from a cohort of men who have sex with men (MSM) in China was evaluated using diagnosis records and LAg-Avidity EIA. Based on partial pol genes, HIV genotypes in 120 recent, 68 long-term, and 54 chronic infections were identified. The CD4 count, CD8 count, and VL, as well as trajectories of dynamic CD4 counts during ART of local PLWH with different HIV subtypes, were compared using non-parametric tests. RESULTS For the HIV database, the CD4 count in PLWH with CRF01_AE was lower than that in PLWH with CRF07_BC or subtype B. For the recently infected local PLWH, CRF01_AE was the dominant HIV subtype (65.83%), followed by CRF07_BC (18.33%) and subtype B (15.83%). Recent CRF01_AE infections showed a lower baseline CD4 count than CRF07_BC infections. During ART for recently infected PLWH, the CD4 count in the CRF01_AE group rapidly increased to reach a peak at the end of the first year post-ART, while the CD4 count in the CRF07_BC group increased slowly to reach a plateau at the end of the third year. The CD4 count in the subtype B group increased significantly to reach a plateau within the first two years and then its trajectory overlapped with that of the CRF07_BC group at the end of the third year post-ART. CONCLUSIONS CRF01_AE rapidly reduced CD4 count during the recent HIV infection. The CD4 count of the recently infected individuals with CRF01_AE increased sharply and reached its highest level of recovery within the first year of ART initiation. This study revealed an important time point for estimating CD4 count recovery post-ART in individuals with different HIV subtypes.
Collapse
Affiliation(s)
- Xue-Ying Zhang
- Department of Microbiology, Harbin Medical University, Harbin, China
| | - Li Wang
- Department of Infectious Diseases, Heilongjiang Provincial Hospital, Harbin, China
| | - Yue Jiang
- Department of Microbiology, Harbin Medical University, Harbin, China
| | - Si-Miao Huang
- Department of Microbiology, Harbin Medical University, Harbin, China
| | - Hong-Rui Zhu
- Department of Microbiology, Harbin Medical University, Harbin, China
| | - Wei Liu
- Department of Microbiology, Harbin Medical University, Harbin, China
| | - Jia-Ye Wang
- Department of Microbiology, Harbin Medical University, Harbin, China
| | - Xiang-Hui Wei
- Department of Microbiology, Harbin Medical University, Harbin, China
| | - Yi-Lin Zhao
- Department of Microbiology, Harbin Medical University, Harbin, China
| | - Wen-Juan Wei
- Center for AIDS/STD Treatment, Harbin Sixth Hospital, Harbin, China
| | - Teng Fei
- Clinical Laboratory, Heilongjiang Provincial Hospital, Harbin, China
| | - Xiao-Hong Chen
- Department of Infectious Diseases, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, China
| | - Dan Wang
- AIDS Diagnosis and Treatment Center of Heilongjiang Province, Infectious Disease Hospital of Heilongjiang Province, Harbin, China
| | - Jin-Liang Li
- Center for AIDS/STD Treatment, Harbin Sixth Hospital, Harbin, China
| | - Hong Ling
- Department of Microbiology, Harbin Medical University, Harbin, China.
- Heilongjiang Provincial Key Laboratory of Infection and Immunity, Harbin, China.
- Key Laboratory of Pathogen Biology, Harbin, China.
| | - Min Zhuang
- Department of Microbiology, Harbin Medical University, Harbin, China.
- Heilongjiang Provincial Key Laboratory of Infection and Immunity, Harbin, China.
- Key Laboratory of Pathogen Biology, Harbin, China.
| |
Collapse
|
2
|
Zhang X, Dong L, Zhou T, Chen H, Han Y, Jin X, Dai J, Yang M, Zeng Z, Sun P, Ma Y, Shi Y, Chen M, Jia M. Analysis of HIV-1 recent infections and hotspot areas in a bordering area in Yunnan Province, China. BMC Public Health 2025; 25:1122. [PMID: 40128682 PMCID: PMC11934778 DOI: 10.1186/s12889-025-21877-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2024] [Accepted: 02/10/2025] [Indexed: 03/26/2025] Open
Abstract
BACKGROUND Honghe Prefecture, located on the China-Vietnam border, has long suffered from HIV-1. To accurately assess the HIV-1 prevalence situation and promote precise prevention and treatment of AIDS, a recent infection surveillance was conducted to explore the at-risk subpopulations and hotspot areas of HIV-1 transmission in Honghe Prefecture. METHODS Combined with the recent infection testing algorithm, HIV-1 recency assay was used to differentiate recent HIV-1 infections among newly reported HIV-1 cases in Honghe Prefecture from 2021 to 2022. Factors associated with recent HIV-1 infection were analyzed by logistic regression. The hotspot areas of recent infections were analyzed by spatial scanning statistics. RESULTS Of the 2698 HIV-1-infected individuals enrolled in this study (no HIV-2 cases reported), 297 HIV-1 cases were classified as recent HIV-1 infection, and the proportion of recent infection was 11.0%. Females (AOR = 2.61, 95% CI: 1.98-3.43), young people (15-34 years old) (AOR = 1.71, 95% CI: 1.21-2.43), highly educated people (AOR = 2.04, 95% CI: 1.24-3.37), men who have sex with men (MSM) (AOR = 3.08, 95% CI: 1.74-5.46), and spouses/regular sexual partners of HIV-1-positive individuals (AOR = 1.96, 95% CI: 1.15-3.33) were more likely to be detected as recent infections. Among the subpopulations by sex, age and transmission route, heterosexually exposed women aged 15-34 years (OR = 1.85, 95% CI: 1.07-3.19) and 35-49 years (OR = 1.65, 95% CI: 1.05-2.58) and MSM aged 15-34 years (OR = 5.11, 95% CI: 2.73-9.59) had a higher proportion of recent infections. Among the subpopulations by mode of exposure and sex, men infected through homosexual contact (OR = 5.59, 95% CI: 3.30-9.47) and women infected through non-marital non-commercial heterosexual contact (OR = 2.10, 95% CI: 1.50-2.95) and positive spousal exposure (OR = 3.03, 95% CI: 1.96-4.69) had a higher proportion of recent infections. With regard to detection methods, women detected by provider-initiated HIV testing counseling (PITC) (OR = 2.03, 95% CI: 1.50-2.76) and spouse/sexual partner testing (OR = 4.10, 95% CI: 2.19-7.67) had a higher proportion of recent infections. A statistically significant spatial cluster of recent infections was found in one county, Yuanyang. CONCLUSIONS This study investigated the use of HIV-1 recency testing in combination with HIV-1 case report surveillance. Correlation factor analysis revealed the presence of distinct risk subpopulations. The spatial distribution of recent infections showed differences. These findings were important for assessing the transmission risk and developing the targeted measures for interventions. CLINICAL TRIAL NUMBER Not applicable.
Collapse
Affiliation(s)
- Xiao Zhang
- Yunnan Provincial Key Laboratory of Public Health and Biosafety & School of Public Health, Kunming Medical University, Kunming, Yunnan, China
| | - Lijuan Dong
- Yunnan Provincial Key Laboratory of Public Health and Biosafety & Institute for AIDS/STD Control and Prevention, Yunnan Center for Disease Control and Prevention, Kunming, Yunnan, China
| | - Tao Zhou
- Division for AIDS/STD Control and Prevention, Honghe Center for Disease Control and Prevention, Honghe, Yunnan, China
| | - Huichao Chen
- Yunnan Provincial Key Laboratory of Public Health and Biosafety & Institute for AIDS/STD Control and Prevention, Yunnan Center for Disease Control and Prevention, Kunming, Yunnan, China
| | - Yu Han
- Yunnan Provincial Key Laboratory of Public Health and Biosafety & Institute for AIDS/STD Control and Prevention, Yunnan Center for Disease Control and Prevention, Kunming, Yunnan, China
| | - Xiaomei Jin
- Yunnan Provincial Key Laboratory of Public Health and Biosafety & Institute for AIDS/STD Control and Prevention, Yunnan Center for Disease Control and Prevention, Kunming, Yunnan, China
| | - Jie Dai
- Yunnan Provincial Key Laboratory of Public Health and Biosafety & Institute for AIDS/STD Control and Prevention, Yunnan Center for Disease Control and Prevention, Kunming, Yunnan, China
| | - Min Yang
- Yunnan Provincial Key Laboratory of Public Health and Biosafety & Institute for AIDS/STD Control and Prevention, Yunnan Center for Disease Control and Prevention, Kunming, Yunnan, China
| | - Zhijun Zeng
- Yunnan Provincial Key Laboratory of Public Health and Biosafety & Institute for AIDS/STD Control and Prevention, Yunnan Center for Disease Control and Prevention, Kunming, Yunnan, China
| | - Pengyan Sun
- Yunnan Provincial Key Laboratory of Public Health and Biosafety & Institute for AIDS/STD Control and Prevention, Yunnan Center for Disease Control and Prevention, Kunming, Yunnan, China
| | - Yanling Ma
- Yunnan Provincial Key Laboratory of Public Health and Biosafety & Institute for AIDS/STD Control and Prevention, Yunnan Center for Disease Control and Prevention, Kunming, Yunnan, China
| | - Yuhua Shi
- Yunnan Provincial Key Laboratory of Public Health and Biosafety & Institute for AIDS/STD Control and Prevention, Yunnan Center for Disease Control and Prevention, Kunming, Yunnan, China.
| | - Min Chen
- Yunnan Provincial Key Laboratory of Public Health and Biosafety & Health Laboratory Center, Yunnan Center for Disease Control and Prevention, Kunming, Yunnan, China.
| | - Manhong Jia
- Yunnan Provincial Key Laboratory of Public Health and Biosafety & Institute for AIDS/STD Control and Prevention, Yunnan Center for Disease Control and Prevention, Kunming, Yunnan, China.
| |
Collapse
|
3
|
Domaoal RA, Vuong J, Zheng A, Detorio M, Parekh BS, Yufenyuy EL. Determination of the mean duration of recent infection and false recency rate for the HIV triplex multiplex bead assay. PLoS One 2024; 19:e0311829. [PMID: 39453903 PMCID: PMC11508083 DOI: 10.1371/journal.pone.0311829] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2024] [Accepted: 09/25/2024] [Indexed: 10/27/2024] Open
Abstract
BACKGROUND We developed the HIV Triplex multiplex bead assay to identify and serotype HIV infection with high sensitivity and specificity; and distinguish recent from long-term HIV-1 infections. It can facilitate accurate incidence estimation, while reducing the number of tests and blood collected, which is highly desirable for use in future studies and surveys. Using previously collected, treatment-naive longitudinal seroconversion HIV-1 positive panels and specimens from individuals infected for >12 months, we determined the assay's mean duration of recent infection (MDRI) and false-recency rate (FRR) respectively, at various mean fluorescent intensity (MFI) cutoffs. METHODS We tested seroconversion specimens (N = 814) from 142 individuals infected with HIV-1 subtypes B, C, or AE, and 1341 cross-sectional specimens from individuals infected >12 months. The MFI cutoffs of 1000 to 2000 were evaluated for recency classification, including an MFI of 1250 corresponding to the limiting antigen avidity enzyme immunoassay (LAg-EIA) cutoff of 1.5 normalized optical density for MDRI and FRR. We used four statistical methods: Methods 1 and 2 used the empirically balanced observation time approach. Method 2 MFI values were raised to power = 1.33, based on a repeated measures model to linearize the relationship between MFI and time points, whereas Method 1 was not linearized. Methods 3 and 4 employed quadratic and linear interpolations for each seroconversion panel. FRR was calculated by dividing the number of specimens misclassified as recent by the total number of specimens tested. RESULTS MDRI values ranged from 135-146 days at MFI = 1000 to 229-279 days at MFI = 2000 by the 4 methods. FRR varied from 0.15%-1.27% with increasing MFI cutoff. At MFI = 1250, the average MDRI of 4 methods was 169 days and ranged from 159-183 with overlapping 95% CIs and FRR = 0.52%. CONCLUSION The HIV Triplex assay demonstrates a longer dynamic range compared to current HIV recency assays with a low FRR for cutoffs examined. With a longer dynamic range and low FRR, the MDRI for recent infection can be extended as appropriate to detect more recent infections, increasing the value of incidence assays benefiting public health surveillance and future surveys.
Collapse
Affiliation(s)
- Robert A. Domaoal
- Division of Global HIV & TB, Centers for Disease Control and Prevention, Atlanta, GA, United States of America
| | - Jeni Vuong
- Division of Global HIV & TB, Centers for Disease Control and Prevention, Atlanta, GA, United States of America
| | - Amy Zheng
- Division of Global HIV & TB, Centers for Disease Control and Prevention, Atlanta, GA, United States of America
- Global Health Fellowship Program, Public Health Institute/Centers for Disease Control, Atlanta, GA, United States of America
| | - Mervi Detorio
- Division of Global HIV & TB, Centers for Disease Control and Prevention, Atlanta, GA, United States of America
| | - Bharat S. Parekh
- Division of Global HIV & TB, Centers for Disease Control and Prevention, Atlanta, GA, United States of America
| | - Ernest L. Yufenyuy
- Division of Global HIV & TB, Centers for Disease Control and Prevention, Atlanta, GA, United States of America
| |
Collapse
|
4
|
Schaefer R, Donaldson L, Leus M, Osakwe CE, Chimukangara B, Dalal S, Duerr A, Gao F, Glidden DV, Grinsztejn B, Justman J, Kumwenda G, Laeyendecker O, Lee HY, Maldarelli F, Mayer KH, Murray J, Parekh BS, Rice B, Robertson MN, Saito S, Vannappagari V, Warren M, Zeballos D, Zinserling J, Miller V. Promising results of HIV prevention trials highlight the benefits of collaboration in global health: The perspective of the Forum HIV Recency Assay Working Group. PLOS GLOBAL PUBLIC HEALTH 2024; 4:e0003878. [PMID: 39446892 PMCID: PMC11501012 DOI: 10.1371/journal.pgph.0003878] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/26/2024]
Affiliation(s)
- Robin Schaefer
- Forum for Collaborative Research, University of California, Berkeley, Washington, District of Columbia, United States of America
| | - Logan Donaldson
- Forum for Collaborative Research, University of California, Berkeley, Washington, District of Columbia, United States of America
| | - Mitchell Leus
- Forum for Collaborative Research, University of California, Berkeley, Washington, District of Columbia, United States of America
| | - Chukwunomso E. Osakwe
- Forum for Collaborative Research, University of California, Berkeley, Washington, District of Columbia, United States of America
| | | | - Shona Dalal
- Global HIV, Hepatitis, and STIs Programmes, World Health Organization, Geneva, Switzerland
| | - Ann Duerr
- Fred Hutchinson Cancer Center, Seattle, Washington, United States of America
| | - Fei Gao
- Fred Hutchinson Cancer Center, Seattle, Washington, United States of America
| | - David V. Glidden
- University of California, San Francisco, California, United States of America
| | - Beatriz Grinsztejn
- Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz (INI-Fiocruz), Rio de Janeiro, Brazil
| | - Jessica Justman
- ICAP at Columbia University, Mailman School of Public Health, New York, New York, United States of America
| | | | - Oliver Laeyendecker
- National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
| | - Ha Youn Lee
- Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America
| | - Frank Maldarelli
- National Cancer Institute, Bethesda, Maryland, United States of America
| | - Kenneth H. Mayer
- The Fenway Institute, Fenway Health, Boston, Massachusetts, United States of America
- Department of Medicine, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, Massachusetts, United States of America
| | - Jeffrey Murray
- Independent consultant, Lewes, Delaware, United States of America
| | - Bharat S. Parekh
- Division of Global HIV & TB, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
| | - Brian Rice
- The University of Sheffield, Sheffield, United Kingdom
| | | | - Suzue Saito
- ICAP at Columbia University, Mailman School of Public Health, New York, New York, United States of America
| | | | | | - Diana Zeballos
- Instituto de Saúde Coletiva, Universidade Federal da Bahia, Salvador, Bahia, Brazil
| | - Jörg Zinserling
- Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany
| | - Veronica Miller
- Forum for Collaborative Research, University of California, Berkeley, Washington, District of Columbia, United States of America
| |
Collapse
|
5
|
Zhou Y, Chen Y, Lu J, Zhang Z, Sun Q, Liu X, Xu X, Ya X, Hu H. Sustained high HIV incidence among men who have sex with men in Jiangsu province, China: based on the limiting-antigen avidity EIA method and six consecutive surveys, 2016-2021. Front Public Health 2023; 11:1277570. [PMID: 38054072 PMCID: PMC10694440 DOI: 10.3389/fpubh.2023.1277570] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2023] [Accepted: 10/25/2023] [Indexed: 12/07/2023] Open
Abstract
Background The epidemic of HIV infection among men who have sex with men (MSM) is a major public health concern in some parts of China, but data on trends in HIV incidence are limited. This study aimed to examine the trends in HIV incidence and factors associated with recent HIV infection among MSM in Jiangsu province, China, based on the limiting-antigen avidity enzyme immunoassay (LAg-Avidity-EIA) method. Methods Six consecutive surveys were implemented among MSM throughout Jiangsu province from 2016 to 2021. Participants were recruited in three ways. Socio-demographic and behavioral information were collected through face-to-face interviews. Venous blood samples were taken to test for HIV and syphilis. HIV incidence was estimated using the LAg-Avidity-EIA method. Chi-square trend tests were used to observe trends over the years. Multivariate regression analyses were used to identify factors associated with recent HIV infection. Results A total of 15,401 participants were enrolled in the study. The prevalence of HIV infection ranged from 8.0 to 9.8%, with no consistent rise or fall over the years (P = 0.189). HIV incidence ranged from 5.0 to 9.0%, and no uptrend or downtrend was shown (P = 0.418). MSM who lived locally for more than 2 years (aOR = 1.366, P = 0.019), had a lack of comprehensive HIV knowledge (aOR = 1.643, P = 0.031), had engaged in unprotected anal intercourse (UAI) in the past 6 months (aOR = 7.373, P < 0.001), had been tested for HIV within 12 months (aOR = 1.292, P = 0.035), and tested positive for syphilis (aOR = 2.840, P < 0.001) were likely to be recently infected with HIV. Conclusions HIV incidence among MSM has remained at a high level in Jiangsu province. In China, health education, condom use, and HIV/syphilis testing should continue to be top priorities for HIV prevention among MSM to reduce HIV transmission.
Collapse
Affiliation(s)
- Ying Zhou
- Institute of STD/AIDS Control and Prevention, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
| | - Yuheng Chen
- Institute of STD/AIDS Control and Prevention, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
| | - Jing Lu
- Institute of STD/AIDS Control and Prevention, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
| | - Zhi Zhang
- Institute of STD/AIDS Control and Prevention, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
| | - Qi Sun
- Institute of STD/AIDS Control and Prevention, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
| | - Xiaoyan Liu
- Institute of STD/AIDS Control and Prevention, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
| | - Xiaoqin Xu
- Institute of STD/AIDS Control and Prevention, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
| | - Xuerong Ya
- Section of STD/AIDS Control and Prevention, Suzhou Municipal Center for Disease Control and Prevention, Suzhou, China
| | - Haiyang Hu
- Institute of STD/AIDS Control and Prevention, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
| |
Collapse
|
6
|
Chen X, Du C, Zhao Q, Zhao Q, Wan Y, He J, Yuan W. Rapid and visual identification of HIV-1 using reverse transcription loop-mediated isothermal amplification integrated with a gold nanoparticle-based lateral flow assay platform. Front Microbiol 2023; 14:1230533. [PMID: 37502395 PMCID: PMC10368893 DOI: 10.3389/fmicb.2023.1230533] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2023] [Accepted: 06/27/2023] [Indexed: 07/29/2023] Open
Abstract
Human immunodeficiency virus type one (HIV-1) infection remains a major public health problem worldwide. Early diagnosis of HIV-1 is crucial to treat and control this infection effectively. Here, for the first time, we reported a novel molecular diagnostic assay called reverse transcription loop-mediated isothermal amplification combined with a visual gold nanoparticle-based lateral flow assay (RT-LAMP-AuNPs-LFA), which we devised for rapid, specific, sensitive, and visual identification of HIV-1. The unique LAMP primers were successfully designed based on the pol gene from the major HIV-1 genotypes CRF01_AE, CRF07_BC, CRF08_BC, and subtype B, which are prevalent in China. The optimal HIV-1-RT-LAMP-AuNPs-LFA reaction conditions were determined to be 68°C for 35 min. The detection procedure, including crude genomic RNA isolation (approximately 5 min), RT-LAMP amplification (35 min), and visual result readout (<2 min), can be completed within 45 min. Our assay has a detection limit of 20 copies per test, and we did not observe any cross-reactivity with any other pathogen in our testing. Hence, our preliminary results indicated that the HIV-1-RT-LAMP-AuNPs-LFA assay can potentially serve as a useful point-of-care diagnostic tool for HIV-1 detection in a clinical setting.
Collapse
Affiliation(s)
- Xu Chen
- The Second Clinical College, Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China
- Clinical Medical Laboratory of the Second Affiliated Hospital, Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China
| | - Cheng Du
- Department of Anesthesiology, The Second Affiliated Hospital, Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China
| | - Qiang Zhao
- Clinical Laboratory, Guizhou Provincial Center for Clinical Laboratory, Guiyang, Guizhou, China
| | - Qi Zhao
- Gastroenterology of the Second Affiliated Hospital, Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China
| | - Yonghu Wan
- Experiment Center, Guizhou Provincial Centre for Disease Control and Prevention, Guiyang, Guizhou, China
| | - Jun He
- Clinical Laboratory, Guizhou Provincial Center for Clinical Laboratory, Guiyang, Guizhou, China
| | - Wei Yuan
- Department of Quality Control, Guizhou Provincial Center for Clinical Laboratory, Guiyang, Guizhou, China
| |
Collapse
|
7
|
Parkin N, Gao F, Grebe E, Cutrell A, Das M, Donnell D, Duerr A, Glidden DV, Hughes JP, Murray J, Robertson MN, Zinserling J, Lau J, Miller V. Facilitating Next-Generation Pre-Exposure Prophylaxis Clinical Trials Using HIV Recent Infection Assays: A Consensus Statement from the Forum HIV Prevention Trial Design Project. Clin Pharmacol Ther 2023; 114:29-40. [PMID: 36550769 DOI: 10.1002/cpt.2830] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2022] [Accepted: 12/08/2022] [Indexed: 12/24/2022]
Abstract
Standard-of-care HIV pre-exposure prophylaxis (PrEP) is highly efficacious, but uptake of and persistence on a daily oral pill is low in many settings. Evaluation of alternate PrEP products will require innovation to avoid the unpractically large sample sizes in noninferiority trials. We propose estimating HIV incidence in people not on PrEP as an external counterfactual to which on-PrEP incidence in trial subjects can be compared. HIV recent infection testing algorithms (RITAs), such as the limiting antigen avidity assay plus viral load used on specimens from untreated HIV positive people identified during screening, is one possible approach. Its feasibility is partly dependent on the sample size needed to ensure adequate power, which is impacted by RITA performance, the number of recent infections identified, the expected efficacy of the intervention, and other factors. Screening sample sizes to support detection of an 80% reduction in incidence for 3 key populations are more modest, and comparable to the number of participants in recent phase III PrEP trials. Sample sizes would be significantly larger in populations with lower incidence, where the false recency rate is higher or if PrEP efficacy is expected to be lower. Our proposed counterfactual approach appears to be feasible, offers high statistical power, and is nearly contemporaneous with the on-PrEP population. It will be important to monitor the performance of this approach during new product development for HIV prevention. If successful, it could be a model for preventive HIV vaccines and prevention of other infectious diseases.
Collapse
Affiliation(s)
- Neil Parkin
- Data First Consulting, Sebastopol, California, USA
| | - Fei Gao
- Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
| | - Eduard Grebe
- Vitalant Research Institute, San Francisco, California, USA
- Edward Grebe Consulting, Cape Town, South Africa
| | - Amy Cutrell
- ViiV Healthcare, Research Triangle Park, North Carolina, USA
| | - Moupali Das
- Gilead Sciences, Foster City, California, USA
| | - Deborah Donnell
- Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
| | - Ann Duerr
- Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
| | | | | | | | | | - Joerg Zinserling
- Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM), Bonn, Germany
| | - Joseph Lau
- Forum for Collaborative Research, Washington, DC, USA
| | | |
Collapse
|